Even fewer patients worldwide consider 2018 pricing policies fair, survey finds

ViiV Healthcare has again finished the highest-ranked pharma company in terms of its corporate reputation, according to 1,500 patient groups from 78 countries who were surveyed by PatientView for the Corporate Reputation of Pharma 2018 global report.

The GlaxoSmithKline (LSE: GSK) majority-owned HIV subsidiary finished top of the pile in the 2018 survey (see below for rankings), as it did in the previous year, with the most important factors considered by the respondents including having a patient-centered strategy, high-quality patient information, safety, transparency and engagement, among others.

US biotech Gilead Sciences (Nasdaq: GILD) edged up one place to second, while the Johnson & Johnson (NYSE: JNJ) unit Janssen moved up two spots to third, Novartis (NOVN: VX) retained its fourth place from last year and AbbVie (NYSE: ABBV), which came second last year, also made it into the top five of the 46 companies included.